478 related articles for article (PubMed ID: 28068672)
1. Genomic hallmarks of localized, non-indolent prostate cancer.
Fraser M; Sabelnykova VY; Yamaguchi TN; Heisler LE; Livingstone J; Huang V; Shiah YJ; Yousif F; Lin X; Masella AP; Fox NS; Xie M; Prokopec SD; Berlin A; Lalonde E; Ahmed M; Trudel D; Luo X; Beck TA; Meng A; Zhang J; D'Costa A; Denroche RE; Kong H; Espiritu SM; Chua ML; Wong A; Chong T; Sam M; Johns J; Timms L; Buchner NB; Orain M; Picard V; Hovington H; Murison A; Kron K; Harding NJ; P'ng C; Houlahan KE; Chu KC; Lo B; Nguyen F; Li CH; Sun RX; de Borja R; Cooper CI; Hopkins JF; Govind SK; Fung C; Waggott D; Green J; Haider S; Chan-Seng-Yue MA; Jung E; Wang Z; Bergeron A; Dal Pra A; Lacombe L; Collins CC; Sahinalp C; Lupien M; Fleshner NE; He HH; Fradet Y; Tetu B; van der Kwast T; McPherson JD; Bristow RG; Boutros PC
Nature; 2017 Jan; 541(7637):359-364. PubMed ID: 28068672
[TBL] [Abstract][Full Text] [Related]
2. Genomic Analysis of Localized High-Risk Prostate Cancer Circulating Tumor Cells at the Single-Cell Level.
Rangel-Pozzo A; Liu S; Wajnberg G; Wang X; Ouellette RJ; Hicks GG; Drachenberg D; Mai S
Cells; 2020 Aug; 9(8):. PubMed ID: 32784507
[TBL] [Abstract][Full Text] [Related]
3. Genomic, pathological, and clinical heterogeneity as drivers of personalized medicine in prostate cancer.
Fraser M; Berlin A; Bristow RG; van der Kwast T
Urol Oncol; 2015 Feb; 33(2):85-94. PubMed ID: 24768356
[TBL] [Abstract][Full Text] [Related]
4. Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer.
Quigley DA; Dang HX; Zhao SG; Lloyd P; Aggarwal R; Alumkal JJ; Foye A; Kothari V; Perry MD; Bailey AM; Playdle D; Barnard TJ; Zhang L; Zhang J; Youngren JF; Cieslik MP; Parolia A; Beer TM; Thomas G; Chi KN; Gleave M; Lack NA; Zoubeidi A; Reiter RE; Rettig MB; Witte O; Ryan CJ; Fong L; Kim W; Friedlander T; Chou J; Li H; Das R; Li H; Moussavi-Baygi R; Goodarzi H; Gilbert LA; Lara PN; Evans CP; Goldstein TC; Stuart JM; Tomlins SA; Spratt DE; Cheetham RK; Cheng DT; Farh K; Gehring JS; Hakenberg J; Liao A; Febbo PG; Shon J; Sickler B; Batzoglou S; Knudsen KE; He HH; Huang J; Wyatt AW; Dehm SM; Ashworth A; Chinnaiyan AM; Maher CA; Small EJ; Feng FY
Cell; 2018 Jul; 174(3):758-769.e9. PubMed ID: 30033370
[TBL] [Abstract][Full Text] [Related]
5. The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impact.
van Dessel LF; van Riet J; Smits M; Zhu Y; Hamberg P; van der Heijden MS; Bergman AM; van Oort IM; de Wit R; Voest EE; Steeghs N; Yamaguchi TN; Livingstone J; Boutros PC; Martens JWM; Sleijfer S; Cuppen E; Zwart W; van de Werken HJG; Mehra N; Lolkema MP
Nat Commun; 2019 Nov; 10(1):5251. PubMed ID: 31748536
[TBL] [Abstract][Full Text] [Related]
6. The genomic landscape of prostate cancer.
Spans L; Clinckemalie L; Helsen C; Vanderschueren D; Boonen S; Lerut E; Joniau S; Claessens F
Int J Mol Sci; 2013 May; 14(6):10822-51. PubMed ID: 23708091
[TBL] [Abstract][Full Text] [Related]
7. Intratumoral and Intertumoral Genomic Heterogeneity of Multifocal Localized Prostate Cancer Impacts Molecular Classifications and Genomic Prognosticators.
Wei L; Wang J; Lampert E; Schlanger S; DePriest AD; Hu Q; Gomez EC; Murakam M; Glenn ST; Conroy J; Morrison C; Azabdaftari G; Mohler JL; Liu S; Heemers HV
Eur Urol; 2017 Feb; 71(2):183-192. PubMed ID: 27451135
[TBL] [Abstract][Full Text] [Related]
8. Genomic and phenotypic heterogeneity in prostate cancer.
Haffner MC; Zwart W; Roudier MP; True LD; Nelson WG; Epstein JI; De Marzo AM; Nelson PS; Yegnasubramanian S
Nat Rev Urol; 2021 Feb; 18(2):79-92. PubMed ID: 33328650
[TBL] [Abstract][Full Text] [Related]
9. Integrative clinical genomics of advanced prostate cancer.
Robinson D; Van Allen EM; Wu YM; Schultz N; Lonigro RJ; Mosquera JM; Montgomery B; Taplin ME; Pritchard CC; Attard G; Beltran H; Abida W; Bradley RK; Vinson J; Cao X; Vats P; Kunju LP; Hussain M; Feng FY; Tomlins SA; Cooney KA; Smith DC; Brennan C; Siddiqui J; Mehra R; Chen Y; Rathkopf DE; Morris MJ; Solomon SB; Durack JC; Reuter VE; Gopalan A; Gao J; Loda M; Lis RT; Bowden M; Balk SP; Gaviola G; Sougnez C; Gupta M; Yu EY; Mostaghel EA; Cheng HH; Mulcahy H; True LD; Plymate SR; Dvinge H; Ferraldeschi R; Flohr P; Miranda S; Zafeiriou Z; Tunariu N; Mateo J; Perez-Lopez R; Demichelis F; Robinson BD; Schiffman M; Nanus DM; Tagawa ST; Sigaras A; Eng KW; Elemento O; Sboner A; Heath EI; Scher HI; Pienta KJ; Kantoff P; de Bono JS; Rubin MA; Nelson PS; Garraway LA; Sawyers CL; Chinnaiyan AM
Cell; 2015 May; 161(5):1215-1228. PubMed ID: 26000489
[TBL] [Abstract][Full Text] [Related]
10. High-risk prostate cancer: a disease of genomic instability.
Tapia-Laliena MA; Korzeniewski N; Hohenfellner M; Duensing S
Urol Oncol; 2014 Nov; 32(8):1101-7. PubMed ID: 24931269
[TBL] [Abstract][Full Text] [Related]
11. Successful whole-exome sequencing from a prostate cancer bone metastasis biopsy.
Van Allen EM; Foye A; Wagle N; Kim W; Carter SL; McKenna A; Simko JP; Garraway LA; Febbo PG
Prostate Cancer Prostatic Dis; 2014 Mar; 17(1):23-7. PubMed ID: 24366412
[TBL] [Abstract][Full Text] [Related]
12. Single cell genomics reveals activation signatures of endogenous SCAR's networks in aneuploid human embryos and clinically intractable malignant tumors.
Glinsky GV
Cancer Lett; 2016 Oct; 381(1):176-93. PubMed ID: 27497790
[TBL] [Abstract][Full Text] [Related]
13. Non-coding and coding genomic variants distinguish prostate cancer, castration-resistant prostate cancer, familial prostate cancer, and metastatic castration-resistant prostate cancer from each other.
Alanazi IO; Al Shehri ZS; Ebrahimie E; Giahi H; Mohammadi-Dehcheshmeh M
Mol Carcinog; 2019 Jun; 58(6):862-874. PubMed ID: 30644608
[TBL] [Abstract][Full Text] [Related]
14. Spatial genomic heterogeneity within localized, multifocal prostate cancer.
Boutros PC; Fraser M; Harding NJ; de Borja R; Trudel D; Lalonde E; Meng A; Hennings-Yeomans PH; McPherson A; Sabelnykova VY; Zia A; Fox NS; Livingstone J; Shiah YJ; Wang J; Beck TA; Have CL; Chong T; Sam M; Johns J; Timms L; Buchner N; Wong A; Watson JD; Simmons TT; P'ng C; Zafarana G; Nguyen F; Luo X; Chu KC; Prokopec SD; Sykes J; Dal Pra A; Berlin A; Brown A; Chan-Seng-Yue MA; Yousif F; Denroche RE; Chong LC; Chen GM; Jung E; Fung C; Starmans MH; Chen H; Govind SK; Hawley J; D'Costa A; Pintilie M; Waggott D; Hach F; Lambin P; Muthuswamy LB; Cooper C; Eeles R; Neal D; Tetu B; Sahinalp C; Stein LD; Fleshner N; Shah SP; Collins CC; Hudson TJ; McPherson JD; van der Kwast T; Bristow RG
Nat Genet; 2015 Jul; 47(7):736-45. PubMed ID: 26005866
[TBL] [Abstract][Full Text] [Related]
15. The molecular biology of prostate cancer: current understanding and clinical implications.
Gandhi J; Afridi A; Vatsia S; Joshi G; Joshi G; Kaplan SA; Smith NL; Khan SA
Prostate Cancer Prostatic Dis; 2018 Apr; 21(1):22-36. PubMed ID: 29282359
[TBL] [Abstract][Full Text] [Related]
16. A genomic and epigenomic atlas of prostate cancer in Asian populations.
Li J; Xu C; Lee HJ; Ren S; Zi X; Zhang Z; Wang H; Yu Y; Yang C; Gao X; Hou J; Wang L; Yang B; Yang Q; Ye H; Zhou T; Lu X; Wang Y; Qu M; Yang Q; Zhang W; Shah NM; Pehrsson EC; Wang S; Wang Z; Jiang J; Zhu Y; Chen R; Chen H; Zhu F; Lian B; Li X; Zhang Y; Wang C; Wang Y; Xiao G; Jiang J; Yang Y; Liang C; Hou J; Han C; Chen M; Jiang N; Zhang D; Wu S; Yang J; Wang T; Chen Y; Cai J; Yang W; Xu J; Wang S; Gao X; Wang T; Sun Y
Nature; 2020 Apr; 580(7801):93-99. PubMed ID: 32238934
[TBL] [Abstract][Full Text] [Related]
17. Next generation mapping reveals novel large genomic rearrangements in prostate cancer.
Jaratlerdsiri W; Chan EKF; Petersen DC; Yang C; Croucher PI; Bornman MSR; Sheth P; Hayes VM
Oncotarget; 2017 Apr; 8(14):23588-23602. PubMed ID: 28423598
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Biomarkers Used for Localised Prostate Cancer Management: A Systematic Review.
Lamy PJ; Allory Y; Gauchez AS; Asselain B; Beuzeboc P; de Cremoux P; Fontugne J; Georges A; Hennequin C; Lehmann-Che J; Massard C; Millet I; Murez T; Schlageter MH; Rouvière O; Kassab-Chahmi D; Rozet F; Descotes JL; Rébillard X
Eur Urol Focus; 2018 Dec; 4(6):790-803. PubMed ID: 28753865
[TBL] [Abstract][Full Text] [Related]
19. Genomics and the Immune Landscape of Osteosarcoma.
Wu CC; Livingston JA
Adv Exp Med Biol; 2020; 1258():21-36. PubMed ID: 32767232
[TBL] [Abstract][Full Text] [Related]
20. A genomic classifier improves prediction of metastatic disease within 5 years after surgery in node-negative high-risk prostate cancer patients managed by radical prostatectomy without adjuvant therapy.
Klein EA; Yousefi K; Haddad Z; Choeurng V; Buerki C; Stephenson AJ; Li J; Kattan MW; Magi-Galluzzi C; Davicioni E
Eur Urol; 2015 Apr; 67(4):778-86. PubMed ID: 25466945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
